Literature DB >> 10623844

Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils.

A L Kindzelskii1, Z Yang, G J Nabel, R F Todd, H R Petty.   

Abstract

Previous studies have shown that Ebola virus' secretory glycoprotein (sGP) binds to Fc gamma RIIIB (CD16b) and inhibits L-selectin shedding. In this study, we test the hypothesis that sGP interferes with the physical linkage between CR3 and Fc gamma RIIIB. Neutrophils were stained with rhodamine-conjugated anti-CD16b mAb (which does not inhibit sGP binding) and fluorescein-conjugated anti-CR3 mAb reagents and then incubated in media with or without sGP. Physical proximity between fluorochrome-labeled CR3 and Fc gamma RIIIB on individual cells was measured by resonance energy transfer (RET) imaging, quantitative RET microfluorometry, and single-cell imaging spectrophotometry. Cells incubated with control supernatants displayed a significant RET signal, indicative of physical proximity (<7 nm) between CR3 and Fc gamma RIIIB. In contrast, cells exposed to sGP showed a significant reduction in the CR3-Fc gamma RIIIB RET signal using these methods. Interestingly, colocalization and cocapping of CR3 and Fc gamma RIIIB were not affected, suggesting that the proximity of these two receptors is reduced without triggering dissociation. Thus, sGP alters the physical linkage between Fc gamma RIIIB and CR3.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623844     DOI: 10.4049/jimmunol.164.2.953

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Authors:  Gopi S Mohan; Ling Ye; Wenfang Li; Ana Monteiro; Xiaoqian Lin; Bishu Sapkota; Brian P Pollack; Richard W Compans; Chinglai Yang
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function.

Authors:  Victoria M Wahl-Jensen; Tatiana A Afanasieva; Jochen Seebach; Ute Ströher; Heinz Feldmann; Hans-Joachim Schnittler
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 3.  Ebola virus pathogenesis: implications for vaccines and therapies.

Authors:  Nancy Sullivan; Zhi-Yong Yang; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  Filovirus replication and transcription.

Authors:  Elke Mühlberger
Journal:  Future Virol       Date:  2007-03       Impact factor: 1.831

5.  Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway.

Authors:  Nancy J Sullivan; Mary Peterson; Zhi-yong Yang; Wing-pui Kong; Heinricus Duckers; Elizabeth Nabel; Gary J Nabel
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  sGP serves as a structural protein in Ebola virus infection.

Authors:  Ayaka Iwasa; Masayuki Shimojima; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

7.  Ebolavirus evolves in human to minimize the detection by immune cells by accumulating adaptive mutations.

Authors:  Arunachalam Ramaiah; Vaithilingaraja Arumugaswami
Journal:  Virusdisease       Date:  2016-02-22

8.  Ion channel clustering enhances weak electric field detection by neutrophils: apparent roles of SKF96365-sensitive cation channels and myeloperoxidase trafficking in cellular responses.

Authors:  Andrei L Kindzelskii; Howard R Petty
Journal:  Eur Biophys J       Date:  2005-07-26       Impact factor: 1.733

9.  CD16b associates with high-density, detergent-resistant membranes in human neutrophils.

Authors:  Maria J G Fernandes; Emmanuelle Rollet-Labelle; Guillaume Paré; Sébastien Marois; Marie-Lisane Tremblay; Jean-Luc Teillaud; Paul H Naccache
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

10.  A new Ebola virus nonstructural glycoprotein expressed through RNA editing.

Authors:  Masfique Mehedi; Darryl Falzarano; Jochen Seebach; Xiaojie Hu; Michael S Carpenter; Hans-Joachim Schnittler; Heinz Feldmann
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.